Cyclosporine‐induced gingival overgrowth—Review

Dermatologic TherapyVolume 35, Issue 12 e15912 REVIEW ARTICLE Cyclosporine-induced gingival overgrowth—Review Joanna Chojnacka-Purpurowicz, Corresponding Author Joanna Chojnacka-Purpurowicz [email protected] orcid.org/0000-0002-0718-5701 Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, The University of Warmia and Mazury, Olsztyn, Poland Correspondence Joanna Chojnacka-Purpurowicz, Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, The Municipal Hospital in Olsztyn, Poland Al. Wojska Polskiego 30 Street, 10-229 Olsztyn, Poland. Email: [email protected]Search for more papers by this authorEwa Wygonowska, Ewa Wygonowska Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, The University of Warmia and Mazury, Olsztyn, PolandSearch for more papers by this authorWaldemar Placek, Waldemar Placek Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, The University of Warmia and Mazury, Olsztyn, PolandSearch for more papers by this authorAgnieszka Owczarczyk-Saczonek, Agnieszka Owczarczyk-Saczonek Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, The University of Warmia and Mazury, Olsztyn, PolandSearch for more papers by this author Joanna Chojnacka-Purpurowicz, Corresponding Author Joanna Chojnacka-Purpurowicz [email protected] orcid.org/0000-0002-0718-5701 Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, The University of Warmia and Mazury, Olsztyn, Poland Correspondence Joanna Chojnacka-Purpurowicz, Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, The Municipal Hospital in Olsztyn, Poland Al. Wojska Polskiego 30 Street, 10-229 Olsztyn, Poland. Email: [email protected]Search for more papers by this authorEwa Wygonowska, Ewa Wygonowska Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, The University of Warmia and Mazury, Olsztyn, PolandSearch for more papers by this authorWaldemar Placek, Waldemar Placek Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, The University of Warmia and Mazury, Olsztyn, PolandSearch for more papers by this authorAgnieszka Owczarczyk-Saczonek, Agnieszka Owczarczyk-Saczonek Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, The University of Warmia and Mazury, Olsztyn, PolandSearch for more papers by this author First published: 08 October 2022 https://doi.org/10.1111/dth.15912Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract Drug-induced gingival overgrowth (DIGO) is an undesirable effect resulting from the therapy of one of the three groups of drugs: phenytoin, calcium channel blockers, and cyclosporine A (CsA). It is caused by a fibrous overgrowth leading to gingivitis, periodontitis, and even tooth loss. Possible consequences include tooth decay worsening, pain and difficulty in eating, bleeding gums, and bad breath. The pathomechanism of the hypertrophy is unknown, but there is a correlation between insufficient oral hygiene and the severity of this phenomenon. The gender and age predilection of gingival hyperplasia as a result of CsA therapy is also noticeable. It is most common in children and adolescents of the male sex. The beneficial effect of the removal of tartar and local irritants in reducing the above symptoms has been demonstrated. One of the treatments for DIGO is conventional gingivectomy. The paper is a review article about cyclosporine-induced gingival hyperplasia. CONFLICT OF INTEREST The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported. Open Research DATA AVAILABILITY STATEMENT Data sharing is not applicable to this article as no new data were created or analyzed in this study. Volume35, Issue12December 2022e15912 RelatedInformation